Calimmune  
临床阶段的艾滋病毒基因药物公司

In 2007, Calimmune assembled a world-class team of researchers, clinicians and translational experts in related fields of science and medicine to develop innovative cell-based therapies for HIV. The company formed around stem cell technology discovered in the labs of Nobel Laureate, Dr. David Baltimore (Caltech) and Dr. Irvin Chen (UCLA AIDS Institute) in early 2000.

The unconventional approaches first tested in the labs of these luminaries were aimed at shielding and strengthening the immune system of HIV-positive patients, rather than trying to modify the virus itself. After a decade of refinements to the early technology and breakthroughs in parallel fields of science, the first generation therapy of this platform technology is approaching the clinic for Phase I human trials.

COMPANY CULTURE

Strong leadership, personal accountability, passion and integrity are the guiding principles of our company. Each team member is a vital member of the company, contributing their strengths and skills in their disciplines to reach our singular purpose of bringing a one-time, cost effective therapy to the HIV community.